Who
Jeffrey A. Meckler
Director
Company insider
Files Form 4 as: Director, Travere Therapeutics; Co-Chief Executive Officer, Indaptus Therapeutics; Chief Executive Officer, Intec Pharma; Director, Qlt Inc/bc; Chief Executive Officer, Cocrystal Pharma.
In numbers
- Trades disclosed
- 128
- Buys
- 20
- Sells
- 3
- Bought
- $1.4M
- Sold
- $4.0M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 10 Jul 2012
- Last trade
- 10 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $174K10,000 at $17.44 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $265K10,000 at $26.52 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $111K1,700 at $65.39 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $79K1,200 at $66.15 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $944K14,000 at $67.46 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $211K3,100 at $68.09 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $174K10,000 at $17.44 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $265K10,000 at $26.52 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $111K1,700 at $65.39 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $79K1,200 at $66.15 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $944K14,000 at $67.46 | filing |
| 10 Sep 2026filed 11 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $211K3,100 at $68.09 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
News
Travere (NASDAQ: TVTX) CEO sells 243,735 shares after option exercisesTVTX · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Jeffrey A. Meckler; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.